Overview of Йодомарин

What is Йодомарин? (Iodine Preparation)

Property	Description
Active ingredient	Potassium Iodide (KI)
Form	Oral Tablets
Pharmacological class	Thyroid Hormone Synthesis Regulator
Common use	Prophylaxis of iodine deficiency
Origin	Synthetic (inorganic salt)

Йодомарин is a well-established pharmaceutical preparation classified as a Thyroid Hormone Synthesis Regulator, specifically utilized to provide a stable, non-radioactive source of the essential trace element iodine. This medicine serves as a monocomponent oral drug, meaning its function is entirely derived from its single active ingredient, Potassium Iodide (KI). Its overall public health purpose is to facilitate prophylaxis—the prevention of disorders caused by inadequate dietary iodine intake. The use of Potassium Iodide in this context is supported by clinical recognition and established health guidelines.

What Type of Medicine is Йодомарин? (Identity and Class)

The primary function of Йодомарин is to supplement the body’s store of elemental iodine, which is the fundamental building block for critical thyroid hormones. While Potassium Iodide functions as a Thyroid Blocking Agent in specific contexts, its broader role is to correct nutritional deficits. This confirms the dual identity of the drug as both a therapeutic agent and a prophylactic supplement. As an Iodine preparation, it belongs to the therapeutic group of thyroid functional agents, designed to stabilize hormone production. Йодомарин is specifically positioned for broad age groups, including children, pregnant women, and breastfeeding women, making it an accessible and versatile option for supplementing iodine.

Composition and Form: The Role of Potassium Iodide

The active component in Йодомарин is the synthetic inorganic salt Potassium Iodide (KI), which, upon ingestion, dissociates to release bioavailable iodide ions. This ingredient is formulated into solid, single-dose tablets for predictable elemental delivery. Potassium Iodide is utilized to prevent iodine deficiency when used prophylactically. Choosing this standardized oral form ensures that the essential element is supplied in a reliable way, allowing for its utilization by the thyroid gland for hormone synthesis.

What is the General Purpose of Йодомарин? (Function and Benefit)

The general purpose of this medicine is to guarantee that the thyroid gland receives adequate iodine to fulfill its metabolic responsibilities. By compensating for nutritional gaps, Йодомарин stabilizes the body's primary endocrine balance. This action supports the regulation of overall metabolism and prevents the structural and functional consequences, such as goiter, that arise when the thyroid cannot produce sufficient hormones due to an iodine deficiency. A typical application is its use for individuals living in areas with known iodine-deficient soil to maintain long-term thyroid health.

Regulatory References

Scientific monographs (NIH Bookshelf)

What side effects are possible with Йодомарин?

Possible side effects and safety information

Official regulatory information addresses potential adverse reactions and restrictions primarily within the scope of iodine compounds. The reported side effects involve reactions across several body systems, primarily the endocrine and immune systems.

Adverse Reactions

The most commonly documented adverse reactions reported include gastrointestinal disorders such as nausea, vomiting, and stomach pain, and skin and subcutaneous tissue disorders such as a rash or hives.

Less common but clinically significant effects include severe hypersensitivity reactions (allergic reactions), which may manifest as swelling of the face, lips, or throat (angioedema), or joint pain, and require immediate medical attention.

Specific Safety Concerns

Adverse effects related to prolonged or high-dose use are categorized as symptoms of 'Iodism' (iodide poisoning). These can include a metallic taste in the mouth, burning in the mouth or throat, soreness of the teeth and gums, and confusion.

Disturbances in the Endocrine System are a major concern, specifically the induction of or exacerbation of hyperthyroidism or hypothyroidism.

Restrictions and Patient Considerations

The drug is contraindicated (must not be used) in individuals with a known hypersensitivity or allergy to iodine or any other component of the medicine. It is also restricted in patients with specific rare skin and immune disorders, such as hypocomplementemic urticarial vasculitis and dermatitis herpetiformis.

Population-specific cautions are documented for patients with existing thyroid conditions (e.g., nodular goiter, Graves' disease) and those with impaired renal function, as these conditions may increase the risk of adverse outcomes or the accumulation of the compound. Safety documentation also highlights that the concurrent use of strong iodine compounds with certain other medications, such as potassium-sparing diuretics or ACE inhibitors, requires caution due to an increased risk of hyperkalemia (high potassium levels in the blood).

Overdose and Emergency Response

Overdose and when to seek help

Overdose from Potassium Iodide may present as a chronic syndrome known as Iodism, typically resulting from prolonged, high, or excessive intake. Documented manifestations of Iodism include a characteristic metallic taste in the mouth, a burning sensation in the throat, severe gastrointestinal distress (such as diarrhea or vomiting), increased salivation, and skin effects like acneiform eruptions. The official profile states that the thyroid gland is a primary affected system, with the potential for developing iodine-induced hypothyroidism or hyperthyroidism upon excessive exposure.

Immediate medical attention is required for any manifestation classified as severe or life-threatening. This includes signs of systemic hypersensitivity, such as swelling of the face, lips, or throat (angioedema), difficulty breathing, or severe outcomes like circulatory collapse. If symptoms of Iodism appear, regulatory documents state the medicine should be withdrawn.

Management procedures described in official labeling emphasize symptomatic and supportive treatment, including the correction of fluid and electrolyte imbalance. No specific antidote is known for iodine poisoning. Regulatory information highlights that neonates are at a significantly higher risk for transient hypothyroidism, and patients with pre-existing thyroid disorders or renal impairment require special consideration.

Therapeutic Uses of Йодомарин

Potassium iodide (the active component in Йодомарин) is commonly used to help with two distinct therapeutic scenarios that involve the thyroid. The primary application is considered relevant for easing the symptoms associated with iodine deficiency disorders (IDDs). This is relevant across conditions presenting with systemic or localized discomfort, and is commonly used to help with symptoms where functional stability becomes affected. Supplementation may assist with managing symptoms related to systemic imbalance, and supports general well-being during symptomatic phases.

A second use is applied across domains where additional symptomatic support is needed in contexts involving acute or disruptive episodes. This is used in clinical settings that involve acute or unstable symptom patterns, such as nuclear radiation emergencies. In this scenario, the medicine plays a role in managing symptoms linked to organ-specific functional stress. This measure assists with maintaining functional stability when symptoms create noticeable physiological strain.

“It is commonly used when short-term symptomatic assistance is needed, and provides support that helps ease the overall symptom burden.”

Quick Fact: Supports symptoms related to systemic imbalance

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Йодомарин? (Official Regulatory Information)

Official regulatory guidelines strictly define the populations eligible to use Йодомарин (Potassium Iodide), focusing on absolute prohibitions and specific conditional allowances.

Contraindicated Populations

Use is strictly prohibited in individuals with a known sensitivity to iodides (iodine allergy). The medicine is also formally contraindicated for patients diagnosed with dermatitis herpetiformis or hypocomplementemic vasculitis. A combination of nodular thyroid disease and pre-existing heart disease is also listed as an exclusion criterion.

Age and Physiological Eligibility

Population Group	Regulatory Status
Children & Adolescents	Permitted (over 1 month old)
Pregnant/Lactating Women	Permitted, but repeat dosing is restricted
Adults Over 40	Restricted / Not generally recommended for prophylaxis

Use requires caution and monitoring in patients with pre-existing conditions such as renal function impairment or various thyroid disorders, including Graves’ disease and multinodular goiter. Repeat dosing in neonates (infants under one month) is generally not recommended due to the potential for thyroid suppression.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Potassium Iodide, the active ingredient in Йодомарин, are officially documented in regulatory sources and primarily involve either additive effects on the thyroid axis or risks related to increased potassium load.

Co-administration with Antithyroid Drugs (such as methimazole or propylthiouracil) or Lithium is documented to potentiate the hypothyroid and goitrogenic effects of these medications. This represents a pharmacodynamic interaction where the effects of both substances are additive on thyroid function.

A second major interaction profile concerns the potassium component, which may lead to hyperkalemia when combined with other potassium-retaining agents. Regulatory information states that co-administration with ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), or Potassium-sparing diuretics may result in hyperkalemia and poses a risk of cardiac arrhythmias. This hyperkalemia risk is heightened in patients with renal function impairment.

Furthermore, the administration of Potassium Iodide interferes with radioiodine ( I-131) therapy and diagnostics, necessitating timing restrictions or contraindication to prevent therapeutic interference. Combining with other Iodine-containing drugs (e.g., Amiodarone) is also documented to increase the overall systemic iodine dose and the risk of toxic effects. There are no known pharmacokinetic interactions officially documented with food or alcohol.

Mechanism of Action

The mechanism of Йодомарин is defined by a precise substrate replacement action that enables the thyroid gland to produce T3 and T4 hormones. This action follows a sequence of targeted steps at the molecular and systemic levels.

1. Targeted Substrate Uptake via NIS

This mechanism initiates as the iodide ion ( I^-) actively engages a specific transporter protein, the Sodium-Iodide Symporter (NIS), on the thyroid cell membrane. By supporting high-capacity transport, the NIS ensures a supra-plasma concentration of I^- inside the cell, overcoming the substrate scarcity that limits hormone synthesis.

2. Enzyme-Driven T3/ T4 Biosynthesis

The concentrated iodide is channeled into the Thyroid Hormone Biosynthesis Pathway, serving as the necessary substrate for the key enzyme, Thyroid Peroxidase (TPO). This enzyme-mediated process catalyzes the organification and coupling reactions that ultimately result in the formation of T4 and T3. This mechanism directly completes the biochemical pathway required for hormone output.

3. Endocrine Feedback Loop Stabilization

The presence of adequate T3 and T4 output modulates the Hypothalamic-Pituitary-Thyroid (HPT) axis via a negative feedback loop. Normal hormone levels suppress the release of TSH (Thyroid-Stimulating Hormone), which in turn removes the chronic TSH stimulus on the thyroid follicular cells. This physiological adjustment prevents TSH-mediated follicular cell hyperplasia.

Dosage and Administration Information

How to Use Йодомарин: Official Administration Guidelines

Administration of Йодомарин (Potassium Iodide, KI) follows official instructions based on the intended purpose, which is either long-term iodine prophylaxis or acute KI thyroid blocking. The sole approved route of administration for this medicine is oral.

Official Dosing and Frequency

Usage Context	Standard Adult Dose	Frequency
Iodine Prophylaxis	150 mu g of elemental iodine	Once daily (chronic)
Acute Thyroid Blocking	130 mg of Potassium Iodide	Once daily (conditional)

Administration Requirements

For long-term prophylaxis, the standard dose is administered daily, but for acute thyroid blocking, administration is strictly conditional upon explicit instruction from public health or emergency officials. This conditional use is further restricted to not exceed one dose every 24 hours. The duration of the acute regimen is limited to the period during which officials advise a risk of exposure.

Population-Specific Adjustments: Official guidelines recommend a higher daily prophylactic dose, typically mathbf220 mu g to mathbf250 mu g of elemental iodine, for pregnant and breastfeeding women. For acute use, the milligram dose must be adjusted by age and weight for children. To facilitate administration, especially in children, the tablets may be crushed or dissolved in water, milk, or juice.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Йодомарин

The research base for the active component in Йодомарин (Potassium Iodide) is drawn from a variety of studies, ranging from large public health observational reports to short-term, specific clinical trials. This overview describes what the research has explored for the medicine’s established uses, using only the findings reported in authoritative scientific literature without providing clinical recommendations.

Evidence for Iodine Deficiency Prophylaxis and Correction

Research exploring the contexts of nutritional iodine deficiency prevention primarily involves large-scale observational cohort studies and non-randomized intervention trials conducted globally. These studies were used in research exploring how long-term public health programs may influence population health.

Researchers monitored outcomes such as the prevalence of goiter (thyroid enlargement) and physical thyroid volume in different communities over time. Studies also monitored specific biomarkers, including changes in urinary iodine concentration (UIC) and serum levels of Thyroid-Stimulating Hormone (TSH), which are used in research contexts involving the assessment of functional balance. Findings described patterns of increased urinary iodine concentration and changes in thyroid volume in certain study groups over follow-up periods ranging from several months up to a year. For instance, some trials described the measurement of less change in thyroid volume in pregnant women using the intervention compared to controls.

What is still uncertain is the influence of other potential confounding factors in large-scale community studies, making it challenging to fully attribute measured changes to the iodine component alone. Additionally, long-term outcomes regarding the durability of measured changes or thyroid function after the intervention is stopped are not always fully established.

Evidence for Acute Thyroid Blocking in Radiological Emergencies

The evidence for this acute, thyroid-blocking context is derived largely from scientific and regulatory data, single-dose pharmacodynamic trials in healthy volunteers, and observational follow-up data from populations exposed during historical incidents. This research examined how the medicine was associated with inhibiting radioactive iodine uptake by the thyroid gland, which is a factor studied in relation to later risks, such as thyroid cancer, especially in younger populations.

Scientific modeling and single-dose trials described a pattern related to rapid thyroid gland saturation following administration. Research highlights that the duration of the acute blocking action following a single dose against radioactive iodine uptake was generally assessed over 24 hours. Long-term epidemiological tracking, such as data from the Chernobyl accident, was used in studies examining later thyroid cancer incidence in those who did or did not receive intervention.

A key limitation is the ethical inability to conduct Randomized Controlled Trials (RCTs) in true emergency scenarios, which means regulatory conclusions rely heavily on scientific modeling and observational patterns. Safety and efficacy data for repeated high-dose administration, which can be applied in research contexts involving fluctuating or unstable symptoms, are limited, as the initial acute blocking action is the most studied effect.

Evidence for Use in Pre-Surgical Thyroid Management

Studies have explored the use of the medicine for a very short-term (7 to 10 day) preparation before thyroid surgery, primarily in patients with conditions like Graves' disease. Research was designed to measure thyroid gland vascularity (blood flow) and intraoperative blood loss during the procedure.

Short-term trials reported the measurement of changes in vascularity within the thyroid gland following the brief preoperative administration period. Surgical outcome studies described quantified blood loss patterns in the administered group compared to controls. However, studies focusing on episodes where symptoms become more noticeable also reported that results were mixed in assessing whether this administration was associated with changes in surgical outcomes or post-operative complications.

Key limitations include that the sample sizes were modest in some comparative trials, limiting the generalizability of findings. Furthermore, follow-up durations were limited to the immediate preoperative and surgical window, meaning little data exists for the research context of later-stage recurrence or long-term functional stability.

Long-Term Studies and Follow-up Data

The available long-term data differs significantly based on the indication. For iodine deficiency prophylaxis, evidence includes extended epidemiological follow-up spanning decades, which contributes to the broader evidence landscape by monitoring population-level outcomes like goiter rates. These data show patterns related to functional measures when supplementation programs are maintained.

In contrast, the long-term data for the acute thyroid blocking indication is retrospective, relying on post-incident tracking of large populations to assess potential long-term risks like thyroid cancer. Findings help contextualize how patients reported their experience and long-term health, but the long-term effects of taking the medicine for its own sake are not fully established outside of the emergency context. For pre-surgical use, data focusing on the durability of the surgical outcome or remission rates beyond the initial recovery period are often not the primary focus of the short-term preparation studies.

Evidence in Special Populations

Specific research has been conducted for populations that are highly vulnerable to iodine deficiency. Studies were evaluated in children and during pregnancy and lactation, where iodine sufficiency is critical.

For iodine deficiency prophylaxis, intervention trials and cohort studies have focused specifically on pregnant women to monitor outcomes like maternal and fetal thyroid function and thyroid volume. Research highlights changes measured during the study period for both the mother and the newborn, but evidence quality varies across studies, with some being non-randomized. Similarly, children are a primary focus in public health research due to their high vulnerability.

For the thyroid blocking indication, regulatory analysis prioritizes these groups—infants, children, and pregnant/nursing females—as those most vulnerable to the effects of radioactive iodine exposure. However, follow-up durations were limited for infants receiving more than one dose in emergency settings.

What Is Still Uncertain About Йодомарин Research

While research describes patterns related to the medicine's effects in specific contexts, several areas remain insufficiently studied.

Long-term effects are not fully established regarding the use of high doses over an extended period, particularly outside of the iodine deficiency context.
Subgroup findings are uncertain for individuals with specific pre-existing thyroid conditions, as most large-scale prophylaxis data focus on healthy populations.
The evidence relies on scientific modeling for the acute radiological indication, as true comparative evidence is lacking from controlled trials in an emergency setting.
Follow-up durations were limited in many of the short-term pre-surgical studies, meaning little data exists for the research context of later-stage recurrence or long-term functional stability.
Research provides insight into short-term changes, but does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References Potassium iodide (oral route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Йодомарин (FAQ)

Q: What does it mean that Йодомарин "supports" the thyroid?

Official documents describe the medicine's mechanism as providing the necessary iodide substrate (a building block). This iodide is used by the thyroid gland to produce its own essential hormones, T3 and T4. In turn, regulating the supply of this substrate is associated with helping regulate the gland's size.

Q: Is Йодомарин ever used for conditions other than iodine deficiency?

Yes, official indications show two main uses beyond deficiency prophylaxis (prevention). The medicine is also used for acute thyroid blocking in radiation emergencies and in pre-surgical preparation for specific thyroid conditions.

Q: Can Йодомарин help with a small goiter?

The primary official purpose of the medicine is the prevention of goiter (thyroid enlargement) due to iodine deficiency. For an already existing goiter, the medicine provides the necessary iodine substrate, but studies indicate that its effect on reducing existing goiter size is not guaranteed across all study groups.

Q: What is the difference between Йодомарин and other kelp or seaweed supplements?

Йодомарин is a standardized, synthetic pharmaceutical preparation of Potassium Iodide (KI). This ensures that every dose contains a specific and consistent amount of iodine. In contrast, kelp or seaweed are natural sources that may contain a variable and less predictable amount of iodine.

Q: Can Йодомарин cause changes in weight?

Weight changes (either gain or loss) are not listed as a direct side effect of the medicine itself. However, official information notes that adverse effects can include endocrine system disturbances, and weight changes are possible signs of underlying thyroid problems (such as hypothyroidism or hyperthyroidism).

Q: Does the time of day matter for how the medicine works?

Official regulatory dosing defines the frequency as once daily for chronic use or once every 24 hours for acute use. Regulatory documents do not specify a particular time of day (morning versus evening) for chronic administration.

Q: Does Йодомарин cross into breast milk, and what does this mean for the baby?

Official warnings state that Potassium Iodide is excreted in breast milk. If used by a nursing mother, this may cause adverse effects in the infant, including skin rash or potentially thyroid suppression. Official information highlights this risk, which is why caution and monitoring are generally recommended.

Q: Can children safely use the same formulation as adults?

The same tablet formulation is typically used for children, and it can be crushed or dissolved in liquid to make administration easier. However, official information indicates that the dose of Potassium Iodide requires careful adjustment by age and weight for children, especially in emergency use contexts.

Q: Is Йодомарин only for preventing an iodine deficiency?

No. According to official regulatory documents, the medicine is used for prophylaxis of deficiency but is also officially indicated for acute thyroid blocking in radiation emergencies. Research also documents its use in pre-surgical management of certain thyroid conditions.

Q: What are the public signs that a person might have low iodine levels?

Official health sources describe signs of low iodine levels as including an enlarged thyroid gland (goiter). Other potential symptoms are those associated with an underactive thyroid, such as dry skin, tiredness, and unexpected weight gain.

Q: Does taking Йодомарин long-term create any known risks?

Regulatory warnings indicate that prolonged or repeated exposure can potentially cause damage to the thyroid gland. Specific documented risks include the induction or exacerbation of hyperthyroidism or hypothyroidism, as well as the formation of a thyroid goiter.

Q: Why is a previous overactive thyroid listed as a reason not to use this medicine?

The medicine is officially contraindicated (prohibited for use) in patients with a previous overactive thyroid because iodide therapy can induce or exacerbate hyperthyroidism (an overactive thyroid condition) or cause other serious thyroid-related adverse effects.

Q: Does Йодомарин affect sleep patterns?

Trouble sleeping is listed in official sources as a possible sign of developing a thyroid problem (either hyper- or hypothyroidism). Since thyroid disturbances are known adverse effects of iodide therapy, trouble sleeping may be an indirect consequence.

Q: Why is it said that iodine can cause both an overactive and an underactive thyroid?

This potential paradox is noted in regulatory information, which documents that iodide therapy may induce or exacerbate either hyperthyroidism (overactive) or hypothyroidism (underactive) in certain individuals, depending on the person's existing thyroid status.

Q: Has the effectiveness of Йодомарин been confirmed by large-scale clinical trials?

The evidence base relies significantly on large-scale observational reports and scientific modeling rather than strictly randomized controlled trials (RCTs). This is because RCTs are often limited or ethically impossible to conduct, especially in emergency use contexts.

Q: What is the World Health Organization’s (WHO) definition of "adequate iodine intake"?

Official government health agencies publish dietary reference intakes (RDAs) based on international standards. The Recommended Dietary Allowance (RDA) for non-pregnant adults is generally cited as 150 \mu g (micrograms)/day of iodine. The RDA for pregnant women is higher, at 220 \mu g (micrograms)/day.

Q: Is Йодомарин the same as taking iodized salt?

No. Iodized salt contains small amounts of iodide for general dietary consumption, but Йодомарин is a specific pharmaceutical preparation of Potassium Iodide. This preparation is used for therapeutic or prophylactic dosing and is highly standardized for consistent elemental delivery.

Q: What are the general informational signs of excessive iodine intake that users should know?

Signs of excessive iodine intake, sometimes referred to as Iodism, can occur with high doses or long-term use. These symptoms may include a metallic taste in the mouth, burning in the throat, sore teeth or gums, and severe headaches.

How should Йодомарин be stored and disposed of?

Storage and Disposal Requirements

Storage and disposal of Йодомарин (Potassium Iodide) must comply strictly with the official requirements stated in regulatory documentation.

Mandatory Storage Conditions

Condition	Requirement
Temperature	Store at room temperature, typically below 25°C (77°F).
Protection	Keep in a dry place and protected from light.
Container	Must remain in the closed original container or pack.
Prohibited	Do not freeze the medicine.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children, as required by labeling. Unused or expired tablets should be disposed of according to local regulations for pharmaceutical waste, which often involves an authorized drug take-back program. Regulatory guidance advises against flushing the medicine down a toilet or pouring it down a sink.

Йодомарин